'''Atipamezole''' (brand name Antisedan, [[Pfizer]]) is a synthetic [[Alpha-2 adrenergic receptor|α<sub>2</sub> adrenergic receptor]] [[adrenergic antagonist|antagonist]], indicated for the reversal of the sedative and analgesic effects of [[dexmedetomidine]] and [[medetomidine]] in dogs.<ref>[http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN Pfizer Animal Health ANTISEDAN Product Overview<!-- Bot generated title -->] {{webarchive |url=https://web.archive.org/web/20080617044114/http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN |date=June 17, 2008 }}</ref>

 
It has also been researched in humans as a potential [[Parkinson's disease#Treatment|anti-Parkinsonian]] drug.<ref name="pmid16389294">{{cite journal |vauthors=Pertovaara A, Haapalinna A, Sirviö J, Virtanen R |title=Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist |journal=CNS Drug Reviews |volume=11 |issue=3 |pages=273–88 |year=2005 |pmid=16389294 |doi= 10.1111/j.1527-3458.2005.tb00047.x|url=}}</ref>
